Área Sanitaria de Ferrol
Área sanitaria
![Foto de Área Sanitaria de Ferrol](/img/noimage.png)
![Foto de Hospital Universitario Doctor Peset](/img/noimage_org.png)
Hospital Universitario Doctor Peset
Valencia, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Doctor Peset (27)
2024
-
Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement — A Multicenter Cross-Sectional CLINI-AEDV Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 36-47
-
Executive Summary of the Spanish Society of Anesthesiology, Reanimation and Pain Therapy (SEDAR), Spanish Society of Emergency and Emergency Medicine (SEMES) and Spanish Society of Otolaryngology, Head and Neck Surgery (SEORL-CCC) Guideline for difficult airway management
Acta Otorrinolaringologica Espanola
-
Spanish Society of Anesthesiology, Reanimation and Pain Therapy (SEDAR) Spanish Society of Emergency and Emergency Medicine (SEMES) and Spanish Society of Otolaryngology, Head and Neck Surgery (SEORL-CCC) Guideline for difficult airway management. Part I
Revista Espanola de Anestesiologia y Reanimacion, Vol. 71, Núm. 3, pp. 171-206
2023
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Stoma-free survival after anastomotic leak following rectal cancer resection: worldwide cohort of 2470 patients
British Journal of Surgery, Vol. 110, Núm. 12, pp. 1863-1876
-
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
Frontiers in Public Health, Vol. 11
2022
-
Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure
Seminars in Arthritis and Rheumatism, Vol. 52
-
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953
-
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Diabetes Therapy, Vol. 13, Núm. 5, pp. 873-888
-
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology
Multiple Sclerosis and Related Disorders, Vol. 63
-
Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study
Minerva Anestesiologica, Vol. 88, Núm. 4, pp. 259-271
-
Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
Acta Dermato-Venereologica, Vol. 102
-
Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study
Journal of Dermatological Treatment, Vol. 33, Núm. 3, pp. 1329-1338
2021
-
Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation
BMC Cardiovascular Disorders, Vol. 21, Núm. 1
-
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis
Scientific Reports, Vol. 11, Núm. 1
2019
-
Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program
Diabetes Therapy, Vol. 10, Núm. 5, pp. 1893-1907
2017
-
Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort
Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942
2016
-
Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)
Medicine (United States), Vol. 95, Núm. 9
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
-
Potential risk for inappropriate dyslipidemia screening in Primary Care in Spain
Revista del Laboratorio Clinico, Vol. 9, Núm. 2, pp. 48-53